Company Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor.
The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 1986 |
| IPO Date | Mar 3, 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 580 |
| CEO | Jon Stonehouse |
Contact Details
Address: 4505 Emperor Boulevard, Suite 200 Durham, North Carolina 27703 United States | |
| Phone | 919 859 1302 |
| Website | biocryst.com |
Stock Details
| Ticker Symbol | BCRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000882796 |
| CUSIP Number | 09058V103 |
| ISIN Number | US09058V1035 |
| Employer ID | 62-1413174 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jon P. Stonehouse | Chief Executive Officer, President and Executive Director |
| Anthony J. Doyle | Senior Vice President, Chief Financial Officer and Interim Principal Accounting Officer |
| Alane P. Barnes | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. Helen M. Thackray FAAP, M.D. | Chief Research and Development Officer |
| Charles K. Gayer | Senior Vice President and Chief Commercial Officer |
| John D. Bluth | Chief Communications Officer |
| Stephanie Angelini | Chief People Officer |
| Dr. William P. Sheridan MBBS | Chief Development Officer |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer |
| Jinky Ang Rosselli | Chief Data and Insights Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 10-K | Annual Report |
| Feb 24, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 8, 2025 | 8-K | Current Report |
| Dec 13, 2024 | 144 | Filing |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |